These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29271929)

  • 1. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
    Aupy P; Echevarría L; Relizani K; Goyenvalle A
    Biomedicines; 2017 Dec; 6(1):. PubMed ID: 29271929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1828():381-394. PubMed ID: 30171555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model.
    Echevarría L; Aupy P; Relizani K; Bestetti T; Griffith G; Blandel F; Komisarski M; Haeberli A; Svinartchouk F; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Jun; 29(3):148-160. PubMed ID: 31009315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy.
    Aupy P; Echevarría L; Relizani K; Zarrouki F; Haeberli A; Komisarski M; Tensorer T; Jouvion G; Svinartchouk F; Garcia L; Goyenvalle A
    Mol Ther Nucleic Acids; 2020 Mar; 19():371-383. PubMed ID: 31881528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.
    Goyenvalle A; Leumann C; Garcia L
    J Neuromuscul Dis; 2016 May; 3(2):157-167. PubMed ID: 27854216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of Exon-Skipping Are Not Artificially Overestimated Because of the Increased Affinity of Tricyclo-DNA-Modified Antisense Oligonucleotides to the Target
    Doisy M; Vacca O; Saoudi A; Goyenvalle A
    Nucleic Acid Ther; 2024 Jul; ():. PubMed ID: 39046946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
    Bizot F; Vulin A; Goyenvalle A
    Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers.
    Goyenvalle A; Griffith G; Babbs A; El Andaloussi S; Ezzat K; Avril A; Dugovic B; Chaussenot R; Ferry A; Voit T; Amthor H; Bühr C; Schürch S; Wood MJ; Davies KE; Vaillend C; Leumann C; Garcia L
    Nat Med; 2015 Mar; 21(3):270-5. PubMed ID: 25642938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides.
    Relizani K; Echevarría L; Zarrouki F; Gastaldi C; Dambrune C; Aupy P; Haeberli A; Komisarski M; Tensorer T; Larcher T; Svinartchouk F; Vaillend C; Garcia L; Goyenvalle A
    Nucleic Acids Res; 2022 Jan; 50(1):17-34. PubMed ID: 34893881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model.
    Relizani K; Griffith G; Echevarría L; Zarrouki F; Facchinetti P; Vaillend C; Leumann C; Garcia L; Goyenvalle A
    Mol Ther Nucleic Acids; 2017 Sep; 8():144-157. PubMed ID: 28918017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of DNA segments in 2'-modified RNA sequences in designing efficient splice switching antisense oligonucleotides.
    Le BT; Agarwal S; Veedu RN
    RSC Adv; 2021 Apr; 11(23):14029-14035. PubMed ID: 35423918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment.
    Robin V; Griffith G; Carter JL; Leumann CJ; Garcia L; Goyenvalle A
    Mol Ther Nucleic Acids; 2017 Jun; 7():81-89. PubMed ID: 28624227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model.
    Bizot F; Fayssoil A; Gastaldi C; Irawan T; Phongsavanh X; Mansart A; Tensorer T; Brisebard E; Garcia L; Juliano RL; Goyenvalle A
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
    Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
    BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
    Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
    Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models.
    Saoudi A; Fergus C; Gileadi T; Montanaro F; Morgan JE; Kelly VP; Tensorer T; Garcia L; Vaillend C; Muntoni F; Goyenvalle A
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.